StockNews.com Downgrades Minerva Neurosciences (NASDAQ:NERV) to Sell

Minerva Neurosciences (NASDAQ:NERV) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday.

Separately, HC Wainwright upped their price target on shares of Minerva Neurosciences from $8.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd.

Minerva Neurosciences Price Performance

NERV stock opened at $4.10 on Friday. The firm has a fifty day moving average price of $6.36 and a two-hundred day moving average price of $7.30. The firm has a market cap of $28.67 million, a price-to-earnings ratio of -0.87 and a beta of 0.24. Minerva Neurosciences has a 1-year low of $1.26 and a 1-year high of $13.22.

Institutional Trading of Minerva Neurosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in Minerva Neurosciences by 150,466.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,517 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 4,514 shares in the last quarter. UBS Group AG lifted its position in shares of Minerva Neurosciences by 914.5% during the 3rd quarter. UBS Group AG now owns 5,732 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 5,167 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Minerva Neurosciences by 8.3% during the 4th quarter. Renaissance Technologies LLC now owns 110,300 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 8,500 shares during the last quarter. Geode Capital Management LLC raised its position in Minerva Neurosciences by 26.5% in the second quarter. Geode Capital Management LLC now owns 51,964 shares of the biopharmaceutical company’s stock valued at $475,000 after purchasing an additional 10,900 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Minerva Neurosciences during the second quarter worth about $192,000. 55.11% of the stock is currently owned by institutional investors and hedge funds.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.